Anemia Correction: Small Step towards Survival in Cancer patients

Author(s): Purvish Parikh, Ankush Gaikwad

Anemia, characterized by hemoglobin levels below 12 gm/dl, is a prevalent comorbidity in cancer patients, with a reported prevalence ranging from 46.5% to 61% in India. Anemia induces tumor hypoxia, angiogenesis, and resistance to conventional chemotherapy and radiotherapy, presenting a barrier to effective cancer treatment. Evidence suggests that correcting anemia can enhance hemoglobin levels, reduce transfusion requirements, and improve quality of life. Anemia consistently correlates with shorter survival times across various cancers, emphasizing its role as an independent risk factor. The article highlights the associations between pretreatment and preoperative anemia and poor survival outcomes in cancer patients undergoing different treatments. The impact of anemia on radiotherapy and chemotherapy outcomes is discussed, emphasizing its correlation with reduced survival and local control. This communication highlights the significance of addressing anemia for improved disease-free survival in specific cancer types. In conclusion, anemia emerges as a detrimental prognostic factor in cancer patients, impacting survival, quality of life, and treatment efficacy. Appropriate interventions for anemia associated with iron deficiency in eligible cancer patients may contribute to improving overall survival outcomes.